Noxilizer, Inc., the company advancing the NO2-based sterilization process for pharmaceutical, biotech and medical device manufacturers, is pleased to announce a 510(k) clearance from the US Food and Drug Administration (FDA) for a medical device terminally sterilized using Noxilizer’s nitrogen dioxide sterilization process.

"Receiving a FDA clearance marks a pivotal milestone for Noxilizer," says Lawrence Bruder, Noxilizer CEO. "This clearance confirms that nitrogen dioxide sterilization is another option for companies – especially for those products, like prefilled syringes, drug-delivery systems and medical devices -- that face challenges with ethylene oxide, gamma radiation or other conventional sterilization methods."

"The FDA spent considerable time and due diligence evaluating the nitrogen dioxide sterilization process, mechanism of action and validation approach," adds Bruder. "Based on work already underway, Noxilizer is very excited that this approval is the first of many more."

Click here to read the entire release via Noxilizer.